KR101186925B1 - Skin Whitening Composition Using a Mulberry Extract - Google Patents
Skin Whitening Composition Using a Mulberry Extract Download PDFInfo
- Publication number
- KR101186925B1 KR101186925B1 KR1020090124551A KR20090124551A KR101186925B1 KR 101186925 B1 KR101186925 B1 KR 101186925B1 KR 1020090124551 A KR1020090124551 A KR 1020090124551A KR 20090124551 A KR20090124551 A KR 20090124551A KR 101186925 B1 KR101186925 B1 KR 101186925B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- present
- skin
- audi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000284 extract Substances 0.000 title claims abstract description 99
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 230000002087 whitening effect Effects 0.000 title claims abstract description 29
- 240000000249 Morus alba Species 0.000 title claims description 10
- 235000008708 Morus alba Nutrition 0.000 title claims description 10
- 239000002537 cosmetic Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 13
- 239000000344 soap Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 4
- 102000003425 Tyrosinase Human genes 0.000 abstract description 17
- 108060008724 Tyrosinase Proteins 0.000 abstract description 17
- 230000002401 inhibitory effect Effects 0.000 abstract description 16
- 230000008099 melanin synthesis Effects 0.000 abstract description 9
- 206010040829 Skin discolouration Diseases 0.000 abstract description 6
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 18
- 210000003491 skin Anatomy 0.000 description 18
- 206010040880 Skin irritation Diseases 0.000 description 16
- 231100000475 skin irritation Toxicity 0.000 description 15
- 230000036556 skin irritation Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 238000000605 extraction Methods 0.000 description 9
- -1 blemishes Chemical compound 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000000419 plant extract Substances 0.000 description 5
- 208000003251 Pruritus Diseases 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000007854 depigmenting agent Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010014970 Ephelides Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000004909 Moisturizer Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000001333 moisturizer Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical class CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 2
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 2
- 101710200814 Melanotropin alpha Proteins 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 150000002989 phenols Chemical group 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 2
- SLYRGJDSFOCAAI-UHFFFAOYSA-N 1,3-thiazolidin-2-one Chemical compound O=C1NCCS1 SLYRGJDSFOCAAI-UHFFFAOYSA-N 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- QFNFXYPFSYJCDF-UHFFFAOYSA-N 1-hydroxy-2h-isoquinolin-3-one Chemical compound C1=CC=CC2=C(O)NC(=O)C=C21 QFNFXYPFSYJCDF-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical class O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 240000002470 Amphicarpaea bracteata Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000208152 Geranium Species 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 240000003394 Malpighia glabra Species 0.000 description 1
- 235000014837 Malpighia glabra Nutrition 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 108010051081 dopachrome isomerase Proteins 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical class CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000002455 scale inhibitor Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- NJRXVEJTAYWCQJ-UHFFFAOYSA-N thiomalic acid Chemical compound OC(=O)CC(S)C(O)=O NJRXVEJTAYWCQJ-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108010014402 tyrosinase-related protein-1 Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D9/00—Compositions of detergents based essentially on soap
- C11D9/04—Compositions of detergents based essentially on soap containing compounding ingredients other than soaps
- C11D9/22—Organic compounds, e.g. vitamins
- C11D9/38—Products in which the composition is not well defined
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 티로시나아제 저해 활성과 멜라닌 생성 억제 활성을 가지는 오디 추출물과 율무 종자 추출물을 이용한 피부 미백제 조성물을 개시한다. The present invention discloses a skin lightening composition using an audi extract and a yulmu seed extract having tyrosinase inhibitory activity and melanin production inhibitory activity.
오디, 추출물, 율무 종자, 미백 Audi, extract, pearl seed, whitening
Description
본 발명은 오디 추출물과 율무 종자 추출물을 이용한 피부 미백제 조성물에 관한 것이다.The present invention relates to a skin lightening composition using an Audi extract and Yulmu seed extract.
피부 미백이 멜라닌 색소와 직접적으로 관련되어 있다는 것은 널리 알려진 사실이다. It is well known that skin whitening is directly related to melanin pigment.
멜라닌은 자외선을 차단하여 진피 이하의 피부 기관을 보호해주는 동시에, 피부 생체 내에 생겨난 자유 라디칼 등에 의한 피부내 단백질과 유전자들의 손상을 보호해 주는 유용한 역할을 하지만, 멜라닌이 필요 이상으로 많이 생기게 되면 피부 노화를 가져오며 기미나 주근깨 등과 같은 과색소침착증을 유발한다.Melanin protects sub-dermal skin organs by blocking UV rays, and protects the damage of proteins and genes in the skin caused by free radicals in the skin. It causes hyperpigmentation such as blemishes and freckles.
멜라닌 합성은 멜라노좀 내에 존재하는 티로시나제 및 티로시나제 관련 단백질(tyrosinase related protein)의 작용에 의하여 이루어진다. 구체적으로 티로시나제(tyrosinase)에 의하여 티로신(tyrosine)이 산화되어 도파(DOPA, 3,4- dihydroxyphenylalanine)로, 이어 도파옥시다제(dopaoxidase)의 작용으로 도파가 다시 산화되어 도파퀴논(dopaquinone)으로 바뀐 후, 티로시나제 관련 단백질인 TRP-1(5,6-dihydroxy indole-2-carboxylic acid oxidase)과 TRP-2(dopachrome tautomerase)의 작용에 의하여 멜라닌을 생성한다. Melanin synthesis is achieved by the action of tyrosinase and tyrosinase related proteins present in the melanosomes. Specifically, tyrosine is oxidized by tyrosinase and is converted into dopa (DOPA, 3,4-dihydroxyphenylalanine), followed by oxidization of dopa oxidase (dopaoxidase) to dopaquinone. In addition, melanin is produced by the action of tyrosinase-related proteins TRP-1 (5,6-dihydroxy indole-2-carboxylic acid oxidase) and TRP-2 (dopachrome tautomerase).
따라서 티로시나아제의 활성이 저해될 경우나 멜라닌의 생성이 억제될 경우 미백 효과를 기대할 수 있다. Therefore, when the activity of tyrosinase is inhibited or the production of melanin is inhibited, a whitening effect can be expected.
대한민국 공개특허 제2008-0105808호(유효성분은 노근으로부터 분리한 페놀성 화합물임), 대한민국 특허 제090535호(유효성분은 목초액으로부터 분리한 페놀성 화합물임) 등이 미백 효과로서 티로시나아제 저해 활성과 멜라닌 생성 억제 활성을 개시하고 있다.Korean Patent Publication No. 2008-0105808 (the active ingredient is a phenolic compound isolated from the root), and Korean Patent No. 090535 (the active ingredient is a phenolic compound isolated from the wood vinegar) as a whitening effect and tyrosinase inhibitory activity And melanin production inhibitory activity is disclosed.
본 발명의 목적은 티로시나아제 저해 활성과 멜라닌 생성 억제 활성을 가지는 오디 추출물과 율무 종자 추출물을 이용한 피부 미백제 조성물에 관한 것이다.An object of the present invention relates to a skin whitening composition using an audi extract and a yulmu seed extract having a tyrosinase inhibitory activity and a melanin production inhibitory activity.
본 발명은 아래의 실시예 및 실험예에서 확인되는 바와 같이, 오디 열수 추출물 및 율무 종자의 열수 추출물이 B16F10 멜라노마 세포에 처리되었을 때, 이들 추출물이 모두 티로시나아제 저해 활성과 멜라닌 생성 억제 활성을 가짐과 함께 이들 추출물이 함께 B16F10 멜라노마 세포에 처리되었을 때는 티로시나아제 저해 활성과 멜라닌 생성 억제 활성이 현저히 높음을 확인함으로써 완성된 것이다. As the present invention is confirmed in the following Examples and Experimental Example, when the hydrothermal extract of the Audi hydrothermal extract and Yulmu seeds were treated to B16F10 melanoma cells, all of these extracts showed tyrosinase inhibitory activity and melanin production inhibitory activity. In addition, when these extracts were treated with B16F10 melanoma cells together, they were completed by confirming that tyrosinase inhibitory activity and melanin production inhibitory activity were remarkably high.
따라서 본 발명의 피부 미백제 조성물은 오디 추출물과 율무 종자 추출물을 유효성분으로 포함함을 특징으로 한다.Therefore, the skin whitening agent composition of the present invention is characterized in that it comprises an Audi extract and Yulmu seed extract as an active ingredient.
본 명세서에서, "오디"란 상실이라고도 하는 뽕나무 열매를 의미하며, 동의보감이나 화한약백과도감에 따르면 당뇨와 오장에 이롭고 부스럼을 치료하고 백발을 검게하는 등 노화 방지 효과가 있다고 알려져 있다.In the present specification, "audi" means a mulberry fruit also known as loss, and according to the synonym of Bogam or Hwahan Encyclopaedia, it is known to be beneficial to diabetes and five intestines and to treat swelling and black hair.
또한 본 명세서에서, "추출물"은 추출 방법을 불문하고 추출 대상을 에탄올, 메탄올, 아세톤, 에틸아세테이트, 포화노말부탄올, 클로로포름, 메틸렌클로라이드, 물 또는 이들의 혼합 용매로 추출하여 얻어진 추출물과 그 추출물에서 상기 열거된 용매로 분획된 추출물을 포함하는 의미로서 이해된다. 추출 방법을 불문하므로, 추 출 대상을 추출 용매에 침지시키는 단계를 통하여 추출되는 한, 추출 방법은 냉침, 환류, 가온, 초음파 등 임의의 방식이 모두 적용될 수 있는 것으로 이해되어야 한다. 그럼에도 상기 추출물은 바람직하게는 추출 대상을 물, 에탄올 또는 이들의 혼합 용매로 추출하고 얻어진 것으로서, 추출 용매가 제거된 농축된 액상의 추출물 또는 고형상의 추출물을 포함하는 의미이다. In addition, in the present specification, "extract" refers to an extract obtained by extracting an extraction object with ethanol, methanol, acetone, ethyl acetate, saturated normal butanol, chloroform, methylene chloride, water or a mixed solvent thereof regardless of the extraction method and the extract thereof. It is understood as meaning including extracts fractionated with the solvents listed above. Regardless of the extraction method, as long as the extraction object is extracted through the step of immersing in the extraction solvent, it should be understood that the extraction method can be applied to any method such as cooling, refluxing, heating, and ultrasonic wave. Nevertheless, the extract is preferably obtained by extracting the object to be extracted with water, ethanol or a mixed solvent thereof, and is meant to include a concentrated liquid extract or solid extract from which the extraction solvent is removed.
또한 본 명세서에서, "피부 미백"은 멜라닌의 생성이 저해됨에 따른 결과로서 이해되는데, 구체적으로는 멜라닌의 생성에 의한 증상, 예컨대 기미, 주근깨, 피부노화 등의 예방, 발현 지연 또는 치료를 의미한다. In addition, in the present specification, "skin whitening" is understood as a result of the inhibition of the production of melanin, specifically, means the prevention, delayed expression or treatment of symptoms caused by the production of melanin, such as blemishes, freckles, skin aging, etc. .
또한 본 명세서에서, "유효성분"이란 단독으로 목적하는 활성을 나타내거나 또는 그 자체는 활성이 없는 담체와 함께 활성을 나타낼 수 있는 성분을 의미한다.In addition, in the present specification, "active ingredient" means a component that can exhibit the desired activity alone or in combination with a carrier that is not active itself.
본 명세서에서 특별히 정의되지 아니한 용어는 국어사전적 의미나 당업계에서 일반적으로 통용되는 의미를 따른다.Terms not specifically defined herein follow the Korean dictionary meaning or meaning commonly used in the art.
본 발명의 피부 미백제 조성물은 그 유효성분인 오디 추출물 추출물과 율무 종자 추출물을 피부 미백 활성을 나타낼 수 있는 한 용도, 제형(화장품, 비누, 연고 등), 배합 목적 등에 따라 임의의 양(유효량)으로 포함할 수 있는데, 통상적인 유효량은 조성물 전체 중량을 기준으로 할 때 0.001 중량 % 내지 99.900 중량 % 범위 내에서 결정될 것이다. 여기서 "유효량"이란 피부 미백 효과를 유도할 수 있는 유효성분의 양을 말한다. 이러한 유효량은 당업자의 통상의 능력 범위 내에서 실험적으로 결정될 수 있다.The skin whitening agent composition of the present invention may be used in any amount (effective amount) according to the use, formulation (cosmetic, soap, ointment, etc.), blending purpose, etc., as long as it can exhibit skin whitening activity of the extracts of the active extracts and the extract of Yulmu as its active ingredients. A typical effective amount will be determined within the range of 0.001% to 99.900% by weight based on the total weight of the composition. Here, the "effective amount" refers to the amount of the active ingredient that can induce a skin lightening effect. Such effective amounts can be determined experimentally within the ordinary skill of those skilled in the art.
본 발명의 피부 미백제 조성물은 유효성분인 오디 추출물 추출물과 율무 종 자 추출물 이외에, 피부 미백 효과를 상승 또는 보강시킬 수 있도록 피부 미백 효과가 있다고 이미 알려진 여타의 공지된 화합물이나 식물 추출물을 포함할 수 있으며, 나아가 앞으로 밝혀질 피부 미백 효과를 갖는 화합물이나 식물 추출물을 포함할 수 있다. The skin lightening composition of the present invention may include other well-known compounds or plant extracts that are known to have a skin whitening effect so as to enhance or enhance the skin whitening effect, in addition to the extracts of the active ingredient and the extract of Yulmu seed, which are the active ingredients. In addition, it may include a compound or plant extract having a skin lightening effect to be revealed in the future.
여기서 상기 여타의 화합물이나 식물 추출물로서는 멀캅토숙신산, 멀캅토덱스트란, 테프레논, 디하이드록시-이소퀴놀린, 인도메타신, 3-하이드록시마뉼, 비타민 K, 티아졸리돈, 키누레닌, 뽕잎 추출물, 뽕나무 줄기 추출물, 뽕나무 뿌리(상백피) 추출물, 레몬 추출물, 오이 추출물, 감초 추출물, 로즈마리 추출물, 아세로라 체리 추출물, 은행 추출물, 카롭(carob) 추출물, 제라늄(geranium) 추출물, 허브 추출물 등을 들 수 있으나, 이에 한정되는 것은 아니다.Herein, the other compounds or plant extracts include mercaptosuccinic acid, mercaptodextran, tefrenone, dihydroxy-isoquinoline, indomethacin, 3-hydroxymanul, vitamin K, thiazolidone, kynurenine, and mulberry leaves. Extracts, mulberry stem extracts, mulberry root extracts, lemon extracts, cucumber extracts, licorice extracts, rosemary extracts, acerola cherry extracts, ginkgo extracts, carob extracts, geranium extracts, herbal extracts, etc. However, the present invention is not limited thereto.
위 예시된 바의 화합물 또는 식물 추출물은 본 발명의 피부 미백제 조성물에 그 유효성분인 오디 추출물과 율무 종자 추출물과 함께 하나 이상 포함될 수 있다. Compounds or plant extracts as exemplified above may be included in the skin whitening agent composition of the present invention together with one or more of the active extracts and the mulberry seed extract.
다른 측면에 있어서, 본 발명은 피부 자극 완화용 조성물에 관한 것이다.In another aspect, the present invention relates to a composition for alleviating skin irritation.
본 발명의 피부 자극 완화용 조성물은 유효성분으로서 오디 추출물 및/또는 율무 종자 추출물을 포함함을 특징으로 한다.The composition for alleviating skin irritation of the present invention is characterized in that it comprises an Audi extract and / or Yulmu seed extract as an active ingredient.
아래의 실험예는 오디 추출물 및/또는 율무 종자 추출물이 포함된 화장팩을 사용할 경우 이들 추출물이 포함되지 아니한 화장팩을 사용할 경우에 비해 피부 자극이 완화되는 결과를 보여준다. The following experimental example shows that skin irritation is alleviated when using a cosmetic pack containing an Audi extract and / or a yulmu seed extract compared to a cosmetic pack containing no extract.
특히 오디 추출물과 율무 종자 추출물이 모두 포함된 경우에 피부 자극 완화 효과가 높다. 따라서 본 발명의 피부 자극 완화용 조성물에는 이들 추출물이 모두 포함되는 것이 바람직하다.In particular, when both the Audi extract and Yulmu seed extract are included, the skin irritation effect is high. Therefore, it is preferable that all of these extracts are included in the composition for alleviating skin irritation of the present invention.
본 명세서에서 "피부 자극 완화"의 의미는 피부 가려움 현상, 피부 따가움 현상 및/또는 홍반이 억제 또는 개선을 의미한다. As used herein, "skin irritation relief" means skin itching, skin itching and / or erythema is suppressed or improved.
본 발명의 피부 미백제 조성물과 피부 자극 완화용 조성물(이하 "본 발명의 조성물")은 구체적인 양태에 있어서, 화장품 조성물로서 파악될 수 있다.The skin whitening agent composition of the present invention and the composition for alleviating skin irritation (hereinafter "composition of the present invention") can be regarded as a cosmetic composition in a specific embodiment.
본 발명의 조성물이 화장품 조성물로서 파악될 경우, 그 화장품 조성물은 다양한 형태로 제조될 수 있는데, 예컨대, 에멀젼, 로션, 크림(수중유적형, 유중수적형, 다중상), 용액, 현탁액(무수 및 수계), 무수 생성물(오일 및 글리콜계), 젤, 마스크, 팩 또는 분말 등의 형태로 제조될 수 있다.When the composition of the present invention is conceived as a cosmetic composition, the cosmetic composition can be prepared in various forms, for example, emulsions, lotions, creams (oil-in-water, water-in-oil, multiphase), solutions, suspensions (anhydrous and Aqueous), anhydrous products (oil and glycol based), gels, masks, packs or powders and the like.
본 발명의 조성물은 오디 추출물과 율무 종자 추출물 이외에 화장품 제제에 있어서 수용가능한 담체를 포함할 수 있다. The composition of the present invention may comprise an acceptable carrier in cosmetic preparations in addition to the Audi extract and the yulmu seed extract.
여기서 "화장품 제제에 있어서 수용가능한 담체"란 화장품 제제에 포함될 수 있는 이미 공지되어 사용되고 있는 화합물 또는 조성물이거나 앞으로 개발될 화합물 또는 조성물로서 피부와의 접촉시 인체가 적응 가능한 이상의 독성, 불안정성 또는 자극성이 없는 것을 말한다.Herein, "acceptable carriers in cosmetic preparations" are compounds or compositions already known and used that may be included in cosmetic preparations, or compounds or compositions which will be developed in the future, which have no toxicity, instability or irritation more than the body can adapt to in contact with the skin. Say that.
상기 담체는 본 발명의 조성물에 그것의 전체 중량에 대하여 약 1 중량 % 내지 약 99.99 중량 %, 바람직하게는 조성물의 중량의 약 50 중량% 내지 약 99 중량 %로 포함될 수 있다. The carrier may be included in the composition of the present invention from about 1% to about 99.99% by weight, preferably from about 50% to about 99% by weight of the composition.
그러나 상기 비율은 본 발명의 화장품의 제조되는 전술한 바의 형태에 따라 또 그것의 구체적인 적용 부위(얼굴이나 손)나 그것의 바람직한 적용량 등에 따라 달라지는 것이기 때문에, 상기 비율은 어떠한 측면으로든 본 발명의 범위를 제한하는 것으로 이해되어서는 안 된다. However, since the ratio depends on the form of the above-described preparation of the cosmetic of the present invention and its specific application site (face or hand) or its preferred application amount, the ratio is in any aspect the scope of the present invention. It should not be understood as limiting.
한편 상기 담체로서는 알코올, 오일, 계면활성제, 지방산, 실리콘 오일, 습윤제, 보습제, 점성 변형제, 유제, 안정제, 자외선 차단제, 발색제, 향료 등이 예시될 수 있다. Examples of the carrier include alcohols, oils, surfactants, fatty acids, silicone oils, humectants, moisturizers, viscosifiers, emulsifiers, stabilizers, sunscreens, coloring agents and perfumes.
상기 담체로서 사용될 수 있는 알코올, 오일, 계면활성제, 지방산, 실리콘 오일, 습윤제, 보습제, 점성 변형제, 유제, 안정제, 자외선 차단제, 발색제, 향료의 성분들은 이미 당업계에 공지되어 있기 때문에 당업자라면 적절한 해당 물질/조성물을 선택하여 사용할 수 있다.The components of the alcohol, oil, surfactant, fatty acid, silicone oil, wetting agent, moisturizer, viscosifier, emulsion, stabilizer, sunscreen agent, coloring agent and fragrance which can be used as the carrier are already well known in the art, The substance / composition can be selected and used.
본 발명의 조성물은 다른 구체적인 양태에 있어 비누 조성물로서 파악될 수 있다.The composition of the present invention may be regarded as a soap composition in another specific embodiment.
본 발명의 조성물이 비누 조성물로서 파악될 경우에, 본 발명의 비누 조성물은 비누 기재에 유효성분인 오디 추출물 및 율무 종자 추출물을 포함하여 제조될 수 있으며, 첨가제로서 피부 보습제, 유화제, 경수연화제 등을 포함하여 제조될 수 있다.When the composition of the present invention is understood as a soap composition, the soap composition of the present invention may be prepared by including an AUDI extract and Yulmu seed extract which are active ingredients on a soap base, and as an additive, a skin moisturizer, an emulsifier, a water softener, and the like. It can be prepared to include.
상기 비누 기재로서는 야자유, 팜유, 대두유, 파마자유, 올리브유, 팜핵류 등의 식물유지 또는 우지, 돈지, 양지, 어유 등의 동물유지 등이 사용될 수 있고, 상기 피부 보습제로서는 글리세린, 에리트리톨, 폴리에틸렌글리콜, 프로필렌글리콜, 부틸렌글리콜, 펜틸렌글리콜, 헥실글리콜, 이소프로필미리스테이트, 실리콘 유도체, 알로에베라, 솔비톨 등이 사용될 수 있으며, 상기 유화제로서는 천연오일, 왁스 지방알콜, 탄화수소류, 천연식물 추출물 등이 사용될 수 있고, 상기 경수연화제로서는 테트라소듐 이디티에이 등이 사용될 수 있다.As the soap base material, vegetable oils such as palm oil, palm oil, soybean oil, perm oil, olive oil, palm kernels, or animal oils such as tallow, pork, sunny and fish oils can be used, and the skin moisturizing agent is glycerin, erythritol and polyethylene glycol. , Propylene glycol, butylene glycol, pentylene glycol, hexyl glycol, isopropyl myristate, silicone derivatives, aloe vera, sorbitol and the like can be used, the emulsifiers include natural oils, wax fatty alcohols, hydrocarbons, natural plant extracts, etc. May be used, and tetrasodium idieti or the like may be used as the water softener.
본 발명의 비누 조성물은 또한 첨가제로서 항균제, 분산제, 거품억제제, 용매, 물때 방지제, 부식 방지제, 향료, 색소, 금속 이온봉쇄제, 산화방지제, 방부제 등을 추가적으로 포함할 수 있다.The soap composition of the present invention may further include an antimicrobial agent, a dispersant, a foam inhibitor, a solvent, a scale inhibitor, a corrosion inhibitor, a perfume, a pigment, a metal ion blocking agent, an antioxidant, a preservative, and the like as an additive.
본 발명의 비누 조성물에 있어서, 비누 기재나 첨가제는 당업계에 일반적으로 사용되고 있는 함량으로 포함될 수 있는데, 비누 기재는 일반적으로 비누 조성물의 전체의 함량을 기준으로 하였을 때 99.9 중량 % 내지 50 중량 %로 첨가될 수 있으며, 첨가제는 1 중량 % 내지 20 중량 %로 첨가될 수 있다. In the soap composition of the present invention, the soap base or additives may be included in an amount generally used in the art, and the soap base is generally 99.9 to 50 wt% based on the total content of the soap composition. It may be added, the additive may be added in 1% to 20% by weight.
한편, 본 발명의 조성물은 다른 구체적인 양태에 있어서 약제학적 조성물로 파악될 수 있다.Meanwhile, the composition of the present invention may be regarded as a pharmaceutical composition in another specific embodiment.
본 발명의 조성물이 약제학적 조성물로 파악될 경우, 그 약리 효과는 멜라닌의 증가에서 비롯되는 질병에 대한 치료 또는 예방 효과로서 파악될 수 있으며, 상기 피부 미백은 상기 질병의 치료 또는 예방의 결과로서 이해될 수 있다. 상기 멜라닌의 증가에서 비롯되는 질병으로서는 기미, 주근깨, 피부 노화 등을 의미한다.When the composition of the present invention is identified as a pharmaceutical composition, the pharmacological effect may be understood as a therapeutic or prophylactic effect for a disease resulting from an increase in melanin, and the skin whitening is understood as a result of the treatment or prevention of the disease. Can be. As a disease resulting from the increase of the melanin means blemishes, freckles, skin aging and the like.
본 발명의 약제학적 조성물은 유효성분인 오디 추출물 및 율물 종자 추출물 이외에 약제학적으로 허용되는 담체, 부형제 등을 포함하여, 경구용 제형(정제, 현탁액, 과립, 에멀젼, 캡슐, 시럽 등), 비경구형 제형(멸균 주사용 수성 또는 유성 현탁액), 국소형 제형(용액, 크림, 연고, 겔, 로션, 패치) 등으로 제조될 수 있다.The pharmaceutical composition of the present invention includes oral formulations (tablets, suspensions, granules, emulsions, capsules, syrups, etc.), parenteral forms, including pharmaceutically acceptable carriers, excipients, etc., in addition to the active extracts and extracts of the seed extract. Formulations (sterile injectable aqueous or oily suspensions), topical formulations (solutions, creams, ointments, gels, lotions, patches) and the like.
상기에서 "약제학적으로 허용되는" 의미는 유효성분의 활성을 억제하지 않으 면서 적용(처방) 대상이 적응가능한 이상의 독성을 지니지 않는다 의미이다.As used herein, "pharmaceutically acceptable" means not inhibiting the activity of the active ingredient, but having no toxicity above that the subject of application (prescription) is adaptable.
약제학적으로 허용되는 담체의 예로서는 락토스, 글루코스, 슈크로스, 전분(예컨대 옥수수 전분, 감자 전분 등), 셀룰로오스, 그것의 유도체(예컨대 나트륨 카르복시메틸 셀룰로오스, 에틸셀룰로오스 등), 맥아, 젤라틴, 탈크, 고체 윤활제(예컨대 스테아르산, 스테아르산 마그네슘 등), 황산 칼슘, 식물성 기름(예컨대 땅콩 기름, 면실유, 참기름, 올리브유 등), 폴리올(예컨대 프로필렌 글리콜, 글리세린 등), 알긴산, 유화제(예컨대 TWEENS), 습윤제(예컨대 라우릴 황산 나트륨), 착색제, 풍미제, 정제화제, 안정화제, 항산화제, 보존제, 물, 식염수, 인산염 완충 용액 등을 들 수 있다. 이러한 담체는 본 발명의 약제학적 조성물의 제형에 따라 적당한 것을 하나 이상 선택하여 사용할 수 있다.Examples of pharmaceutically acceptable carriers include lactose, glucose, sucrose, starch (such as corn starch, potato starch, etc.), cellulose, derivatives thereof (such as sodium carboxymethyl cellulose, ethylcellulose, etc.), malt, gelatin, talc, solids Lubricants (e.g. stearic acid, magnesium stearate, etc.), calcium sulfate, vegetable oils (e.g. peanut oil, cottonseed oil, sesame oil, olive oil, etc.), polyols (e.g. propylene glycol, glycerin, etc.), alginic acid, emulsifiers (e.g. TWEENS), wetting agents (e.g. Sodium lauryl sulfate), colorants, flavoring agents, tableting agents, stabilizers, antioxidants, preservatives, water, saline, phosphate buffer solutions and the like. The carrier may be selected from one or more of suitable pharmaceutical formulations according to the formulation of the pharmaceutical composition of the present invention.
부형제도 본 발명의 약제학적 조성물의 제형에 따라 적합한 것을 선택하여 사용할 수 있는데, 예컨대 본 발명의 약제학적 조성물이 수성 현탁제로 제조될 경우에 적합한 부형제로서는 나트륨 카르복시메틸 셀룰로오스, 메틸 셀룰로오스, 히드로프로필메틸셀룰로오스, 알긴산 나트륨, 폴리비닐피롤리돈 등의 현탁제나 분산제 등을 들 수 있다. 주사액으로 제조되는 경우 적합한 부형제로서는 링거액, 등장 염화나트륨 등을 들 수 있다.Excipients may be selected and used according to the formulation of the pharmaceutical composition of the present invention, for example, when the pharmaceutical composition of the present invention is prepared with an aqueous suspending agent, suitable excipients are sodium carboxymethyl cellulose, methyl cellulose, hydropropylmethylcellulose And suspending agents and dispersing agents such as sodium alginate and polyvinylpyrrolidone. Suitable excipients when prepared from injection solutions include Ringer's solution, isotonic sodium chloride, and the like.
본 발명의 약제학적 조성물은 경구 또는 비경구로 투여될 수 있으나, 통상적으로는 외용제 제형으로 피부에 국소적으로 직접 투여될 것이다. The pharmaceutical compositions of the present invention may be administered orally or parenterally, but will usually be administered topically to the skin, usually in a topical formulation.
본 발명의 약제학적 조성물은 그 1일 투여량이 통상 0.001 ~ 150 mg/kg 체중 범위이고, 1회 또는 수회로 나누어 투여할 수 있다. 그러나 본 발명의 약제학적 조 성물의 투여량은 투여 경로, 환자의 연령, 성별, 체중, 환자의 중증도 등의 여러 관련 인자에 비추어 결정되는 것이므로 상기 투여량은 어떠한 측면으로든 본 발명의 범위를 제한하는 것으로 이해되어서는 아니 된다. The daily dose of the pharmaceutical composition of the present invention is usually 0.001 to 150 mg / kg body weight, and may be administered once or several times. However, since the dosage of the pharmaceutical composition of the present invention is determined in view of various related factors such as the route of administration, the age, sex, weight of the patient, and the severity of the patient, the dosage may limit the scope of the present invention in any aspect. It should not be understood as.
전술한 바와 같이, 본 발명에 따르면 오디 추출물을 이용한 피부 미백제 조성물을 제공할 수 있다. 또한 본 발명에 따르면 피부 자극 완화용 조성물을 제공할 수 있다. 본 발명의 조성물은 화장품, 비누 또는 연고 등의 약품으로 제품화될 수 있다.As described above, according to the present invention, it is possible to provide a skin lightening composition using an Audi extract. In addition, the present invention can provide a composition for alleviating skin irritation. The composition of the present invention can be formulated into a drug such as cosmetics, soap or ointment.
이하 본 발명을 실시예 및 실험예를 참조하여 설명한다. 그러나 본 발명의 범위가 이러한 실시예 및 실험예에 한정되는 것은 아니다.Hereinafter, the present invention will be described with reference to Examples and Experimental Examples. However, the scope of the present invention is not limited to these examples and experimental examples.
<< 실시예Example > > 오디 추출물 및 율무 종자 추출물의 제조Preparation of Audi Extract and Yulmu Seed Extract
<실시예 1> 오디 추출물의 제조 Example 1 Preparation of Audi Extract
오디 50g에 물 1L를 넣고 약 65℃의 온도로 가온하며 12시간 동안 추출하였다. 추출 후 여과시켜 추출 잔사를 제거하고 감암농축하여 고형상의 오디 추출물을 얻었다.1 g of water was added to 50 g of Audi, and heated to a temperature of about 65 ° C. and extracted for 12 hours. After extraction, the resultant was filtered and the residue was extracted.
<실시예 2> 율무 종자 추출물의 제조 Example 2 Preparation of Yulmu Seed Extract
율무 종자 분말 50g에 물 1L를 넣고 약 65℃의 온도로 가온하며 12시간 동안 추출하였다. 추출 후 여과시켜 추출 잔사를 제거하고 감암농축하여 고형상의 율무 종자 추출물을 얻었다.1L of water was added to 50 g of Yulmu seed powder, and heated to a temperature of about 65 ° C. and extracted for 12 hours. After extraction, the resultant was filtered and the residue was extracted and concentrated in dark and dark to obtain a solid Yulmu seed extract.
<< 실험예Experimental Example > > 미백 효과, 아토피 피부염 개선 효과 및 보습 효과 실험Whitening effect, atopic dermatitis improvement effect and moisturizing effect experiment
<실험예 1> 미백 효과 세포실험 Experimental Example 1 Whitening Effect Cell Experiment
<실험예 1-1> B16F10 멜라노마 세포 배양 Experimental Example 1-1 B16F10 Melanoma Cell Culture
B16F10 멜라노마 세포를 10% FBS(fetal bovine serum), 페니실린 100 units/㎖, 스트렙토마이신 100 units/㎖이 포함된 DMEM 배지를 사용하여 37℃, 5% CO2의 유지하며 배양하였으며, 4일에 한 번씩 계대배양을 시행하였다.B16F10 melanoma cells were cultured in DMEM medium containing 10% fetal bovine serum (FBS), 100 units / ml penicillin, and 100 units / ml streptomycin at 37 ° C. and maintained at 5% CO 2 . Subculture was performed once.
<실험예 1-2> 세포독성 평가 Experimental Example 1-2 Cytotoxicity Evaluation
상기 실시예 추출물의 B16F10 세포에 대한 독성을 MTT assay를 이용하여 평가하였다. B16F10 세포(2.0×104 cells/㎖)를 24웰에 분주하고 18시간 배양 후, 시료(10㎍/㎖)(상기 각 실시예의 추출물임)을 처리하여 24시간 동안 더 배양하였다. 여기에 PBS 5㎎/㎖의 농도로 제조한 MTT 용액 200㎕를 첨가하고 4시간을 더 배양하였다. 배양액을 제거하고 각 웰에 DMSO 200㎕를 가하여 MTT 환원에 의하여 생성된 포르마잔을 570㎚에서 흡광도를 측정하였다. Toxicity to the B16F10 cells of the Example extract was evaluated using the MTT assay. B16F10 cells (2.0 × 10 4 cells / ml) were dispensed into 24 wells and cultured for 18 hours, followed by further incubation for 24 hours by treating a sample (10 μg / ml) (the extract of each example above). 200 µl of the MTT solution prepared at a concentration of 5 mg / ml PBS was added thereto, followed by further 4 hours of incubation. The culture solution was removed, and 200 µl of DMSO was added to each well, and the absorbance of the formazan produced by MTT reduction was measured at 570 nm.
결과를 <도 1>에 나타내었다. <도 1>를 참조하여 보면, 상기 실시예의 추출물 모두 특별한 세포 독성을 보이지 않음을 알 수 있다(A: 율무 종자 추출물, B: 오디 추출물). The results are shown in FIG. 1. Referring to Figure 1, it can be seen that the extracts of the above examples do not show any particular cytotoxicity (A: Yulmu seed extract, B: Audi extract).
<실험예 1-3> 티로시나아제 저해 활성 실험 Experimental Example 1-3 Tyrosinase Inhibitory Activity Experiment
B16F10 세포(2.0×104 cells/㎖)를 24웰에 분주한 후, 시료(10㎍/㎖)(상기 실시예의 추출물 또는 <실시예 1>의 추출물과 <실시예 2>의 추출물의 동량의 혼합물)을 처리하여 48시간 동안 배양하였다. 다음 각 웰의 세포를 수거하여 10 mM PBS 100㎕에 현탁시키고 이 현탁액을 볼텍싱한 후 원심분리하여 얻어진 상층액을 효소액으로 사용하였다. 티로시나아제 저해 활성 실험은 24 웰에 상기 상층액 40㎕과 그것의 기질인 L-DOPA(2mg/㎖) 100㎕를 넣고, 37 ℃에서 1시간 동안 반응시킨 후 ELISA 리더를 이용하여 405nm에서 흡광도를 측정하였다. 티로시나아제의 활성을 무처리리군인 대조군의 흡광도에 대한 백분율로 <도 2>에 나타내었다.After dispensing B16F10 cells (2.0 × 10 4 cells / ml) into 24 wells, the sample (10 μg / ml) (the same amount of the extract of Example 1 or the extract of Example 1 and the extract of Example 2) Mixture) and incubated for 48 hours. Next, the cells of each well were collected, suspended in 100 µl of 10 mM PBS, the suspension was vortexed, and the supernatant obtained by centrifugation was used as an enzyme solution. Tyrosinase inhibitory activity experiment was carried out in 24 wells of the supernatant 40μL and its substrate L-DOPA (2mg / ㎖) 100μL, reacted for 1 hour at 37 ℃ and absorbance at 405nm using an ELISA reader Was measured. The activity of tyrosinase is shown in FIG. 2 as a percentage of the absorbance of the untreated group control.
<도 2>를 참조하여 보면, 상기 실시예의 추출물 모두 티로시나아제의 활성을 억제함을 알 수 있다. 특히 오디 추출물과 율무 종자 추출물의 혼합물의 활성이 가장 높다(A: 율무 종자 추출물, B: 오디 추출물). Referring to Figure 2, it can be seen that the extracts of the above examples all inhibit the activity of tyrosinase. In particular, the activity of the mixture of the Audi extract and Yulmu seed extract is the highest (A: Yulmu seed extract, B: Audi extract).
<실험예 1-4> 멜라닌 생성 억제 활성 실험 Experimental Example 1-4 Melanin Production Inhibition Activity Experiment
B16F10 세포(2.0×104 cells/㎖)를 24웰에 분주한 후, 상기 실시예의 각 추출물(10㎍/㎖)을 멜라닌 형성 자극제인α-MSH(50 nM)와 함께 처리하여 72시간 동안 배양하였다. 세포를 수거하여 1N NaOH를 첨가하여 세포를 완전히 용해시킨 후 405nm에서 ELISA로 흡광도를 측정하였다. After dispensing B16F10 cells (2.0 × 10 4 cells / ml) into 24 wells, each extract (10 μg / ml) of the above Example was treated with α-MSH (50 nM), a melanin-forming stimulant, and cultured for 72 hours. It was. Cells were harvested and 1N NaOH was added to completely lyse the cells, and then absorbance was measured by ELISA at 405 nm.
결과를 대조군(α-MSH 처리군)에 대한 백분율로 <도 3>에 나타내었다. <도 3>를 참조하여 보면 실시예의 추출물이 멜라닌의 생성을 억제함을 알 수 있으며, 여기서도 상기 <도 2>의 결과와 유사하게 오디 추출물과 율무 종자 추출물의 혼합물이 멜라닌 생성 억제 활성이 가장 높다(A: 율무 종자 추출물, B: 오디 추출물). The results are shown in FIG. 3 as a percentage of the control group (α-MSH treated group). Referring to FIG. 3, it can be seen that the extract of Example inhibits the production of melanin. Here, similar to the result of FIG. 2, the mixture of the Audi extract and the yulmu seed extract have the highest melanin production inhibitory activity. (A: Yulmu seed extract, B: Audi extract).
<실험예 2> 미백 효과 임상실험 Experimental Example 2 Whitening Effect Clinical Experiment
미백 효과의 임상실험을 위해서 아래 [표 1]과 같은 성분 및 함량으로 화장팩을 제조하였다.For the clinical experiment of the whitening effect was prepared a cosmetic pack with the ingredients and contents as shown in Table 1 below.
[표 1][Table 1]
화장팩의 성분 및 함량(중량 %)Ingredients and content of cosmetic pack (% by weight)
여기서 비교예의 화장팩으로서는 실시예의 추출물 대신에 정제수가 그 함량만큼 포함된 화장팩을 사용하였다. Here, as a cosmetic pack of Comparative Example, a cosmetic pack containing purified water was used instead of the extract of Example.
미백 효과 실험은 20대 여성 20명 및 30대 여성 20명을 대상으로 통상의 사용 방법에 따라 1주일에 2회 4주간 사용하도록 한 후 설문 조사 형식으로 5점 척도법(매우우수(5점), 우수(3점), 보통(0점), 나쁨(-3점), 매우나쁨(-5점))에 따라 평 가하고 그 결과를 아래의 [표 2] 내지 [표 5]에 나타내었다. 평가 항목인 피부자극 여부에 있어서는 피부의 가려움 현상, 피부 따가움 또는 홍반 등의 현상이 완화되었는가를 조사했다.For the whitening effect test, 20 women in their 20s and 20 women in their 30s were used twice a week for 4 weeks according to the usual method of use, and then a 5-point scale method (very good (5 points), Excellent (3 points), moderate (0 points), bad (-3 points), very bad (-5 points) was evaluated according to the results are shown in Tables 2 to 5 below. In the case of skin irritation, which is an evaluation item, it was examined whether the phenomenon of itching, skin itching or erythema of the skin was alleviated.
[표 2][Table 2]
<제조예 1>의 미백 효과에 대한 결과(20대 여성)Results of the whitening effect of <Production Example 1> (Women in 20s)
[표 3][Table 3]
<제조예 1>의 미백 효과에 대한 결과(30대 여성)Results of the whitening effect of <Production Example 1> (women in their 30s)
[표 4][Table 4]
<제조예 2>의 미백 효과에 대한 결과(20대 여성)Results of the whitening effect of <Production Example 2> (women in their 20s)
[표 5][Table 5]
<제조예 2>의 미백 효과에 대한 결과(30대 여성)Results of the whitening effect of <Production Example 2> (women in their 30s)
상기 [표 2] 내지 [표 5]를 참조하여 보면, 실시예의 추출물이 피부 자극을 일으키지 않음은 물론 피부 자극을 완화하는 효과가 있음을 알 수 있다. 또한 비교예에 비해 미백 효과도 뛰어남을 알 수 있다. 특히 오디 추출물과 율무 종자 추출물을 함께 포함된 화장팩의 경우 오디 추출물만이 포함된 화장팩에 비하여 그 미백 효과와 피부 자극 완화 효과가 현저히 뛰어남을 알 수 있다. Referring to the above [Table 2] to [Table 5], it can be seen that the extract of the embodiment does not cause skin irritation and of course, has an effect of alleviating skin irritation. In addition, it can be seen that the whitening effect is also superior to the comparative example. In particular, in the case of a cosmetic pack containing both the Audi extract and Yulmu seed extract, it can be seen that the whitening effect and the skin irritation-reducing effect are remarkably superior to the cosmetic pack containing only the Audi extract.
도 1은 오디 추출물과 율무 종자 추출물이 세포 독성을 가지지 않음을 보여주는 결과이다. 데이타는 3번의 실험의 평균±표준편차로 나타내었다.1 is a result showing that the Audi extract and Yulmu seed extract does not have cytotoxicity. Data is shown as mean ± standard deviation of three experiments.
도 2는 오디 추출물 및/또는 율무 종자 추출물이 티로시나아제 저해 활성을 보여주는 결과이다. 데이타는 3번의 실험의 평균±표준편차로 나타내었다.Figure 2 shows the results of the tyrosinase inhibitory activity of the Audi extract and / or Yulmu seed extract. Data is shown as mean ± standard deviation of three experiments.
도 3은 오디 추출물 및/또는 율무 종자 추출물이 멜라닌 생성 억제 활성을 보여주는 결과이다. 데이타는 3번의 실험의 평균±표준편차로 나타내었다.Figure 3 is a result showing the melanin production inhibitory activity of the mulberry extract and / or yulmu seed extract. Data is shown as mean ± standard deviation of three experiments.
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090124551A KR101186925B1 (en) | 2009-12-15 | 2009-12-15 | Skin Whitening Composition Using a Mulberry Extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090124551A KR101186925B1 (en) | 2009-12-15 | 2009-12-15 | Skin Whitening Composition Using a Mulberry Extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20110067799A KR20110067799A (en) | 2011-06-22 |
KR101186925B1 true KR101186925B1 (en) | 2012-09-28 |
Family
ID=44400181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090124551A Expired - Fee Related KR101186925B1 (en) | 2009-12-15 | 2009-12-15 | Skin Whitening Composition Using a Mulberry Extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101186925B1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102793642B (en) * | 2012-08-28 | 2014-01-15 | 广州丹奇日用化工厂有限公司 | Skin care product composition |
KR101579500B1 (en) * | 2014-03-11 | 2015-12-22 | 재단법인 경기과학기술진흥원 | Skin whitening composition comprising an extract obtained from roots of coix lachryma-jobi var. mayuen |
US11389392B2 (en) | 2017-06-13 | 2022-07-19 | Mary Kay Inc. | Cosmetic compositions and methods for their use in firming skin |
-
2009
- 2009-12-15 KR KR1020090124551A patent/KR101186925B1/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
Korean J. Food Preserve,. vol.16(3), pp.442-448(2009.06.30)* |
Also Published As
Publication number | Publication date |
---|---|
KR20110067799A (en) | 2011-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101132572B1 (en) | Skin Whitening Composition | |
KR101229927B1 (en) | Skin Whitening Composition Using a Litter Extract or a Silk Worm Extract | |
KR101052189B1 (en) | Skin Whitening Composition | |
KR102360881B1 (en) | Composition for improving skin | |
KR101230277B1 (en) | Composition of External Application for Using Bamboo Sprout | |
JP3800611B2 (en) | Whitening agent or pigmentation ameliorating agent | |
KR102275267B1 (en) | Composition for improving skin | |
KR20190137328A (en) | Skin external application composition for anti-aging containing Rhodotypos scandens extract | |
KR20140012456A (en) | Composition for improving skin conditions comprising akebia saponin d | |
KR101186925B1 (en) | Skin Whitening Composition Using a Mulberry Extract | |
CA2588131C (en) | Method and composition for reducing the appearance of wrinkles | |
KR20130052379A (en) | Cosmetics composition for skin lightening color, antioxidantsand and method for preparing the same | |
KR101141929B1 (en) | Skin Whitening Composition | |
KR20080096162A (en) | Skin Whitening Composition | |
KR100865071B1 (en) | Whitening composition containing as active ingredient a tritical extract or a compound separated therefrom | |
KR102525901B1 (en) | Skin external application composition for anti-aging containing Phlox subulata extract | |
KR20190137327A (en) | Skin external application composition for anti-aging | |
KR20210151024A (en) | Composition for improving skin | |
KR101270929B1 (en) | Skin Whitening Composition Using Acanthoic acid isolated from Acanthopanax koreanum Root Bark | |
JP3647295B2 (en) | Lipid peroxide production inhibitor and composition containing the same | |
KR102741071B1 (en) | Composition for improving skin | |
KR102245188B1 (en) | Composition for improving skin | |
KR102431820B1 (en) | Cosmetic composition comprising extract of Citrus grandis Osbeck and Dendropanax morbifera | |
JP3647296B2 (en) | Inhibition of tyrosinase activity and compositions containing the same | |
JP2001114664A (en) | Cosmetic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20091215 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20111019 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20120622 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20120924 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20120924 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20150924 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20150924 Start annual number: 4 End annual number: 4 |
|
LAPS | Lapse due to unpaid annual fee | ||
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20170705 |